ICL-induced miR139-3p and miR199a-3p have opposite roles in hematopoietic cell expansion and leukemic transformation.

Blood
Mir Farshid AlemdehyStefan J Erkeland

Abstract

Interstrand crosslinks (ICLs) are toxic DNA lesions that cause severe genomic damage during replication, especially in Fanconi anemia pathway-deficient cells. This results in progressive bone marrow failure and predisposes to acute myeloid leukemia (AML). The molecular mechanisms responsible for these defects are largely unknown. Using Ercc1-deficient mice, we show that Trp53 is responsible for ICL-induced bone marrow failure and that loss of Trp53 is leukemogenic in this model. In addition, Ercc1-deficient myeloid progenitors gain elevated levels of miR-139-3p and miR-199a-3p with age. These microRNAs exert opposite effects on hematopoiesis. Ectopic expression of miR-139-3p strongly inhibited proliferation of myeloid progenitors, whereas inhibition of miR-139-3p activity restored defective proliferation of Ercc1-deficient progenitors. Conversely, the inhibition of miR-199a-3p functions aggravated the myeloid proliferation defect in the Ercc1-deficient model, whereas its enforced expression enhanced proliferation of progenitors. Importantly, miR-199a-3p caused AML in a pre-leukemic mouse model, supporting its role as an onco-microRNA. Target genes include HuR for miR-139-3p and Prdx6, Runx1, and Suz12 for miR-199a-3p. The latte...Continue Reading

References

Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·D E ZhangD G Tenen
Nov 13, 1999·Nature Cell Biology·J D WeberD Bar-Sagi
Feb 5, 2005·The EMBO Journal·Joanna M PrasherLaura J Niedernhofer
Aug 6, 2005·Science·Ramesh S PillaiWitold Filipowicz
Feb 18, 2006·Molecular Cell·Christian P PetersenPhillip A Sharp
Apr 12, 2006·Proceedings of the National Academy of Sciences of the United States of America·Katharina WagnerDaniel G Tenen
May 31, 2007·Cell Cycle·Kotb AbdelmohsenMyriam Gorospe
Jan 1, 2008·Blood Reviews·Inderjeet Dokal, Tom Vulliamy
Apr 18, 2008·PLoS Biology·Ian J MajewskiDouglas J Hilton
Jun 11, 2008·Molecular and Cellular Biology·Anwaar AhmadLaura J Niedernhofer
Jul 17, 2008·Antioxidants & Redox Signaling·Wei DuQishen Pang
Oct 24, 2009·Blood·Scott M VanderwerfGrover C Bagby
Nov 4, 2009·The Journal of Clinical Investigation·Mallika GhoshTimothy Hla
Apr 27, 2010·Blood Reviews·Akiko Shimamura, Blanche P Alter
May 28, 2010·Stem Cells·Kalindi ParmarAlan D'andrea
Jul 27, 2010·Environmental and Molecular Mutagenesis·Jennifer J RahnRodney S Nairn
Oct 23, 2010·Molecular Cell·Anthony K L Leung, Phillip A Sharp
Nov 9, 2010·Biochemical and Biophysical Research Communications·Jon C HenryThomas D Schmittgen
Jan 18, 2011·Nature Genetics·Yonghwan KimAgata Smogorzewska
Jun 28, 2011·Nature Reviews. Cancer·Andrew J Deans, Stephen C West
Oct 1, 2011·The Journal of Pathology·Gerry P Crossan, Ketan J Patel
Jan 10, 2012·Current Opinion in Pediatrics·Shefali Parikh, Monica Bessler
Mar 20, 2012·Cell·Joshua T Mendell, Eric N Olson
Jul 4, 2012·Genes & Development·Hyungjin Kim, Alan D D'Andrea

❮ Previous
Next ❯

Citations

Mar 16, 2016·Biochimica Et Biophysica Acta·Filomena de Nigris
Mar 26, 2016·Frontiers in Plant Science·Stephanie R BollmannNiklaus J Grünwald
Aug 23, 2016·Current Stem Cell Reports·Christine Roden, Jun Lu
Dec 10, 2016·Blood Cancer Journal·K KrowiorzF Kuchenbauer
Nov 22, 2017·Antioxidants & Redox Signaling·Francesca PacificiDavide Lauro
Jul 15, 2015·Oncogene·S EmmrichJ H Klusmann
Jan 15, 2020·Annals of Hematology·Mingyu LiHongzai Guan
Oct 6, 2016·Oncotarget·Qiong LiaoGuosheng Jiang
Nov 15, 2019·Journal of Clinical Laboratory Analysis·Zhiyong JiangXinguo Luo
Feb 15, 2018·Frontiers in Oncology·Stephanie Rebecca SetijonoSu Jung Song
Feb 2, 2017·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·M K SannigrahiMadhu Khullar
Feb 19, 2021·Haematologica·Stefan J ErkelandAnton W Langerak
Jul 3, 2021·International Journal of Molecular Sciences·Sylwia CiesielskaJoanna Rzeszowska-Wolny
Nov 7, 2021·Leukemia·Christiaan J StavastStefan J Erkeland

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.